A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
It's that time again! Jim Cramer rang the lightning round bell, which means he gave his take on caller favorite stocks at rapid speed:
Stryker Corporation: "I think Stryker is very, very interesting here. The medical device group is good, but I do prefer Edwards Lifesciences Corp more than Stryker."
Johnson & Johnson: "Johnson & Johnson is good and going higher. I have to tell you my charitable trust sold it too soon because we decided that we wanted to have a little more extra with Allergan, but JNJ is OK."
Merck & Co: "You've got JNJ and you've got Merck. I've got to tell you that I think Merck lags JNJ. They don't have that extra growth that I like to see. I would never tell anybody to sell Merck, but I don't like the product profile as much as JNJ."
Unilever: "Boy I like Unilever! The management is really on top of things. They've got the emerging market going really, really well. I think that stock can go up 10 percent. By the way, the strong dollar? It's good for them."
Goldman Sachs: "Goldman Sachs, are you kidding me? I love it! The book value is $176 and that's ridiculous. I think it goes to $210."
China Mobile: "No. The communist party takes too much control over stocks there. After this most recent downturn, I am not recommending any Chinese stocks."
Dyax Corporation: "Oh man, that is just a tough one. It's too speculative for me. It's good for a young person. But way too speculative for most of my people."
GW Pharmaceuticals: "Another one that has been a little too speculative. I've got to tell you, this is one that I got behind very early on. This is marijuana unfortunately for people/kids with epilepsy. But I think the stock is now too speculative given that this is a very tough market for a Celgene or even for a Gilead."
Read more from Mad Money with Jim Cramer
Abiomed: "You know that stock got hammered, and I thought was ridiculous how hard it got hammered! I think it represents great value. That was insane that it went down so much."
Northrop Grumman Corporation: "I think it's absolutely terrific. Northrop Grumman is in a foot race with Lockheed Martin to go higher. NOC won that big bomber contract and I thought it would go to LMT. I like LMT a little more right now at $214, but Northrop is good."
Baidu Inc: "No, I can't. I know that is one that I would love to recommend. But because of this most recent downturn — and they have U.S.-like financials — I do not trust Baidu. I have to be a very tough guy on these Chinese stocks after what happened this summer."